Skip to main content

Table 1 HER2 is amplified in all PAM50 subtypes, and enriched in HER2E

From: HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors

Subtype TCGA (n = 106) Metabric (n = 133) USO1062 (n = 79)
HER2E 48 (45%) 71 (53%) 30 (38%)
Luminal A 19 (18%) 14 (11%) 26 (33%)
Luminal B 32 (30%) 27 (20%) 17 (21%)
Basal-like 7 (7%) 21 (16%) 6 (8%)
  1. Number and percentage of human epidermal growth factor receptor 2 amplified (HER2A) tumors across the prediction analysis of microarray 50 (PAM50) subtypes in The Cancer Genome Atlas (TCGA), Metabric and the USO1062 clinical trial. HER2E HER2-enriched